Using Blood Biomarkers to Differentiate Stroke Types
Author Information
Author(s): Paul Julien F., Ducroux Célina, Correia Pamela, Daigneault Audrey, Larochelle Catherine, Stapf Christian, Gioia Laura C.
Primary Institution: University of Montreal
Hypothesis
Can serum glial fibrillary acidic protein (GFAP) levels help determine stroke type, timeline, and tissue impact in acute stroke patients?
Conclusion
Serum GFAP levels may help distinguish between intracerebral hemorrhage and acute ischemic stroke and provide insights into the timing and extent of ischemic injury.
Supporting Evidence
- GFAP levels were significantly higher in patients with intracerebral hemorrhage compared to other diagnoses.
- GFAP levels increased with longer delays since symptom onset in acute ischemic stroke patients.
- Blood biomarker acquisition is feasible in the emergency setting for suspected acute stroke.
Takeaway
Doctors can check a blood test to see if a patient has a certain type of stroke and how bad it is, which can help them treat the patient better.
Methodology
Blood samples were collected from patients suspected of having an acute stroke and analyzed for GFAP and NfL levels using a sensitive immunoassay.
Potential Biases
The observational nature and lack of blinding may introduce bias in the results.
Limitations
The study is a single-center pilot with a small sample size, limiting the generalizability of the findings.
Participant Demographics
Mean age was 68.5 years, with 44% female participants.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website